Zoltán Kaló

Best Publications

• Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force

  Praveen Thokala;Nancy Devlin;Kevin Marsh;Rob Baltussen

  787
  Citations

• Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force

  Kevin Marsh;Maarten IJzerman;Praveen Thokala;Rob Baltussen

  525
  Citations

• Comparison of weighting methods used in multicriteria decision analysis frameworks in healthcare with focus on low- and middle-income countries.

  Bertalan Németh;Anett Molnár;Sándor Bozóki;Sándor Bozóki;Kalman Wijaya

  134
  Citations

• Cost-effectiveness of organ donation: evaluating investment into donor action and other donor initiatives.

  James F. Whiting;Bryce Kiberd;Zoltan Kalo;Paul Keown

  131
  Citations

• Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group.

  Sandra Nestler-Parr;Daria Korchagina;Mondher Toumi;Chris L. Pashos

  108
  Citations

• The cost effectiveness of Apligraf® treatment of diabetic foot ulcers

  W. Ken Redekop;Joseph McDonnell;Paul Verboom;Kornelia Lovas

  102
  Citations

• Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments.

  W K Redekop;E A Stolk;E Kok;K Lovas

  100
  Citations

• HTA Implementation Roadmap in Central and Eastern European Countries.

  Zoltán Kaló;Adrian Gheorghe;Mirjana Huic;Marcell Csanádi

  97
  Citations

• Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development

  József Bodrogi;Zoltán Kaló

  81
  Citations

• Resource use and treatment costs after kidney transplantation: impact of demographic factors, comorbidities, and complications.

  Ernst-Günther Hagenmeyer;Bertram Häussler;Elke Hempel;Gerrit Grannas

  77
  Citations

• Capacity Building for HTA Implementation in Middle-Income Countries: The Case of Hungary

  Zoltán Kaló;József Bodrogi;Imre Boncz;Imre Boncz;Csaba Dózsa

  70
  Citations

• Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.

  András Inotai;Christiaan P J Prins;Marcell Csanádi;Dinko Vitezic

  67
  Citations

• Implementation of Health Technology Assessment in the Middle East and North Africa: Comparison Between the Current and Preferred Status.

  Ahmad Fasseeh;Rita Karam;Mouna Jameleddine;Mohsen George

  65
  Citations

• The European challenges of funding orphan medicinal products

  Márta Szegedi;Tamás Zelei;Francis Arickx;Anna Bucsics

  63
  Citations

• Economic evaluation of kidney transplantation versus hemodialysis in patients with end-stage renal disease in Hungary

  Zoltán Kaló;Jeno Járay;Júlia Nagy

  60
  Citations

• Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer.

  A.T. Zemplényi;Z. Kaló;G. Kovács;R. Farkas

  58
  Citations

• Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries

  Tamás Zelei;Mária J. Molnár;Márta Szegedi;Zoltán Kaló

  58
  Citations

• Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt

  Gihan H. Elsisi;Zoltán Kaló;Randa Eldessouki;Mahmoud D. Elmahdawy

  57
  Citations

• Healthcare financing in Egypt: a systematic literature review.

  Unknown

  53
  Citations

• Policy objective of generic medicines from the investment perspective: The case of clopidogrel.

  Péter Elek;András Harsányi;Tamás Zelei;Kata Csetneki

  10
  Citations